One target that has been studied for the development of a prophylactic/preventative vaccine is topoisomerase 2 alpha (TOP2A), an important enzyme in DNA replication, cancer cell proliferation and is a direct or indirect target of anticancer agents.135 Using the Cancer Genome Atlas, Lee et al. found that TOP2A was highly expressed in TNBC patients.135 Various TOP2A peptides were tested for Th1 induction efficiency and 3 were selected for the formation of a multi-peptide vaccine. Here, TOP2A is linked to cancer.